Digital Oral Presentations
- DOP01 The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
- DOP02 Single cell RNA sequencing of Ulcerative Colitis and Crohn's Disease tissue samples informs the selection of Triggering Receptors Expressed on Myeloid Cells 1 (TREM1) as a target for the treatment of Inflammatory Bowel Diseases
- DOP03 Unfermented β-fructan fibres can induce gut inflammation and tumorigenesis in select Inflammatory Bowel Disease patients mediated by gut microbiota
- DOP04 Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn’s Disease.
- DOP05 Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients
- DOP06 Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease
- DOP07 Targeting the canonical WNT signalling pathway as a potential novel therapy in Crohn´s associated fibrosis
- DOP08 Cellular and molecular interaction of MAIT in mucosal tissue and their role in inflammatory bowel disease
- DOP09 Eosinophils exert a pro-inflammatory role in a chronic DSS colitis model without an impact on fibrosis
- DOP10 Early intestinal resection in Crohn’s Disease is not associated with severe long-term disease course
- DOP11 A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
- DOP12 Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn’s disease
- DOP13 Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
- DOP14 Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
- DOP15 Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
- DOP16 Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
- DOP17 HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
- DOP18 Brain structural correlates of fatigue in active and quiescent Crohn’s Disease
- DOP19 Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
- DOP20 The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 – 2018
- DOP21 Disease activity patterns of paediatric Inflammatory Bowel Disease – A Danish nationwide cohort study 1996-2018
- DOP22 Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A Population-Based Cohort Study
- DOP23 Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey
- DOP24 Early life exposures and risk for inflammatory bowel disease: a nested case-control study in Quebec, Canada
- DOP25 Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United States
- DOP26 Burden of perianal disease and perianal surgery in Crohn’s disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
- DOP27 Disease activity patterns in the first 5 years after diagnosis in children with Crohn’s disease: a population-based study.
- DOP28 Aconitate decarboxylase 1 (ACOD1) represents a crucial regulator of monocyte recruitment, survival and proinflammatory status in intestinal inflammation
- DOP29 Single cell analysis of Crohn’s disease fistula; comparison of different locations
- DOP30 Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-Omics
- DOP31 Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn’s disease
- DOP32 Crohn’s disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
- DOP33 Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease.
- DOP34 Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel Disease
- DOP35 High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
- DOP36 Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
- DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
- DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy
- DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study
- DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
- DOP41 Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
- DOP42 Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients
- DOP44 Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
- DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
- DOP46 Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
- DOP47 Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
- DOP48 Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn’s disease. The ENIGMA study.
- DOP49 Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn’s disease. The ENIGMA study.
- DOP50 Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
- DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn’s disease patients
- DOP52 The faecal bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn’s disease and the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet
- DOP53 Community types of the human gut virome are associated with endoscopic outcome in UC patients
- DOP54 Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis
- DOP55 The increasing burden of direct and indirect costs of IBD
- DOP56 Long-term disease progression and resective surgery rates in Crohn’s disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
- DOP57 GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study
- DOP58 predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
- DOP59 What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
- DOP60 Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
- DOP61 Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
- DOP62 Medication use is increased in the decade prior to IBD diagnosis: A nationwide cohort study
- DOP63 Time Trends of Environmental and Socio-economical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis
- DOP64 Utilising genomics to predict outcomes and delineate novel subgroups in inflammatory bowel disease
- DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease
- DOP66 Ileal resections from fibrotic-CD patients present microbiota dysbiosis, altered metabolomic profiles and metabolite-sensing GPCRs expression
- DOP67 A transcriptional module associated with neutrophil degranulation is highly conserved across species and is a core molecular pathway of treatment resistance in ulcerative colitis
- DOP68 Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.
- DOP69 Glycans as an actor in the microbiome-immune response crosstalk.
- DOP70 Crohn’s Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
- DOP71 TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
- DOP72 HLA-DQA1*05 associates with immunogenicity and loss of response to anti-TNF therapy in the IBD population: A meta-analysis
- DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
- DOP74 Artificial Intelligence Quantifying Endoscopic Severity of Ulcerative Colitis in Gradation Scale
- DOP75 Video capsule endoscopy may detect active small bowel Crohn’s disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
- DOP76 Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
- DOP77 Is durable remission achievable after ileocolic resection for Crohn’s disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
- DOP78 Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
- DOP79 Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
- DOP80 Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
- DOP81 Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
- DOP82 Biological Treatment Cycles in Crohn’s Disease
- DOP83 Proactive dosing is superior to clinically based dosing in terms of endoscopic healing in paediatric patients with Crohn’s disease receiving maintenance infliximab: A randomized controlled trial
- DOP84 IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational study
- DOP85 Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. Two year results of the STRIDENT Randomised Controlled Trial.
- DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
- DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results
- DOP88 Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s disease
- DOP89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study
- DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab